Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

DE ROOCK W;CLAES B;BERNASCONI D;DE SCHUTTER J;BIESMANS B;FOUNTZILAS G;KALOGERAS KT;KOTOULA V;PAPAMICHAEL D;LAURENT PUIG P;PENAULT LLORCA F;ROUGIER P;VINCENZI B;SANTINI D;TONINI G;CAPPUZZO F;FRATTINI M;MOLINARI F;SALETTI P;DE DOSSO S;MARTINI M;BARDELLI A;SIENA S;SARTORE BIANCHI A;TABERNERO J;MACARULLA T;DI FIORE F;GANGLOFF AO;CIARDIELLO, Fortunato;PFEIFFER P;QVORTRUP C;HANSEN TP;VAN CUTSEM E;PIESSEVAUX H;LAMBRECHTS D;DELORENZI M;TEJPAR S.

2010